ReviewAnnals of translational medicine2015
Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification.
Review in Annals of translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 158 citations in OpenAlex.
- Flash Assembloids: A Rapid Biofabrication of a Platform for Modeling Early Glioblastoma Invasion at the Glioblastoma-Brain Organoid Interfaces.Advanced healthcare materials · 2026Article
- Selective Cytotoxic and Redox-Associated Effects of Plant-Derived Terpenoids in Human Glioblastoma Cells.Cell biochemistry and biophysics · 2026Article
- A novel mitochondrial-related gene signature for assessing the tumor immune microenvironment and predicting prognosis in human glioma.Discover oncology · 2026Article
- Formyl peptide receptor 2 activation by MR-39 inhibits glioblastoma cell proliferation and invasiveness through suppression of multiple oncogenic pathways.Journal of translational medicine · 2026Article
- Integrative Cross-Modal Fusion of Preoperative MRI and Histopathological Signatures for Improved Survival Prediction in Glioblastoma.Bioengineering (Basel, Switzerland) · 2026Article
- PHSP-Net: Personalized Habitat-Aware Deep Learning for Multi-Center Glioblastoma Survival Prediction Using Multiparametric MRI.Bioengineering (Basel, Switzerland) · 2025Article
- Comparison of Quality of Life in Postoperative High-Grade Glioma Patients Treated Using EORTC and RTOG Target Delineation Techniques for Postoperative Radiotherapy.Asian journal of neurosurgery · 2025Article
- A Review of Artificial Intelligence-Based Systems for Non-Invasive Glioblastoma Diagnosis.Life (Basel, Switzerland) · 2025Review
- Current Research Trends in Glioblastoma: Focus on Receptor Tyrosine Kinases.International journal of molecular sciences · 2025Review
- Molecular Determinants for Photodynamic Therapy Resistance and Improved Photosensitizer Delivery in Glioma.International journal of molecular sciences · 2024Review
- Identification of T2W hypointense ring as a novel noninvasive indicator for glioma grade and IDH genotype.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Article
- Machine Learning-Based Prediction of GliomaCancers · 2024Article
- Article
- Marker-controlled watershed algorithm and fuzzy C-means clustering machine learning: automated segmentation of glioblastoma from MRI images in a case series.Annals of medicine and surgery (2012) · 2024Article
- Algorithmic approach utilizing histology and immunohistochemistry for the current classification of diffuse glioma.International journal of clinical and experimental pathology · 2024Article
- Article
- Article
- Article
- Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTraditional classification of diffuse infiltrating gliomas (DIGs) as World Health Organization (WHO) grades II-IV is based on histological features of a heterogeneous population of tumors with varying prognoses and treatments. Over the last decade, research efforts have resulted in a better understanding of the molecular basis of glioma formation as well as the genetic alterations commonly identified in diffuse gliomas.
methodsA systematic review of the current literature related to advances in molecular phenotypes, mutations, and genomic analysis of gliomas was carried out using a PubMed search for these key terms. Data was studied and synthesized to generate a comprehensive review of glioma subclassification.
resultsThis new data helps supplement the existing WHO grading scale by subtyping gliomas into specific molecular groups. The emerging molecular profile of diffuse gliomas includes the studies of gene expression and DNA methylation in different glioma subtypes. The discovery of novel mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) provides new biomarkers as points of stratification of gliomas based on prognosis and treatment response. Gliomas that harbor CpG island hypermethylator phenotypes constitute a subtype of glioma with improved survival. The difficulty of classifying oligodendroglial lineage of tumors can be aided with identification of 1p/19q codeletion. Glioblastomas (GBMs) previously described as primary or secondary can now be divided based on gene expression into proneural, mesenchymal, and classical subtypes and the identification of mutations in the promoter region of the telomerase reverse transcriptase (TERTp) have been correlated with poor prognosis in GBMs.
conclusionsIncorporation of new molecular and genomic changes into the existing WHO grading of DIGs may provide better patient prognostication as well as advance the development of patient-specific treatments and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.